Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 43.77 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 15.19 | Oscillator | Buy |
| Williams %R (14) | -78.43 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.04 (Hist -0.00) | Oscillator | Strong Sell |
| Average Directional Index (14) | 22.74 (+DI 26.1 / -DI 20.6) | Trend | Buy |
Current price $1.83
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 15, 26 |
| EMA 20 | 1.93 | MA | Strong Sell |
| SMA 20 | 1.91 | MA | Strong Sell |
| EMA 50 | 1.97 | MA | Strong Sell |
| SMA 50 | 2.09 | MA | Strong Sell |
| SMA 200 | 2.02 | MA | Strong Sell |
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| Oct 14, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Oct 6, 26 | Morgan Stanley | maintain | Underweight | Underweight |
| Apr 15, 26 | Cantor Fitzgerald | upgrade | Neutral | Overweight |
| Mar 10, 26 | BTIG | upgrade | Neutral | Buy |
| Oct 22, 25 | TD Cowen | downgrade | Buy | Hold |
| Oct 22, 25 | BTIG | downgrade | Buy | Neutral |
| Oct 22, 25 | William Blair | downgrade | Outperform | Market Perform |
| Oct 22, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 14, 26 | Rosenthal Arnon | director, officer: Chief Executive Officer | A-Award | 217,500 | — |
| Oct 14, 26 | Rosenthal Arnon | director, officer: Chief Executive Officer | A-Award | 978,750 @ $1.88 | $1.84M |
| Oct 13, 26 | Rosenthal Arnon | director, officer: Chief Executive Officer | A-Award | 520,000 @ $1.87 | $972.4K |
| Oct 13, 26 | Rosenthal Arnon | director, officer: Chief Executive Officer | A-Award | 500,000 @ $1.87 | $935.0K |
| Oct 13, 26 | Rosenthal Arnon | director, officer: Chief Executive Officer | A-Award | 457,038 @ $1.87 | $854.7K |
| Oct 13, 26 | Rosenthal Arnon | director, officer: Chief Executive Officer | A-Award | 417,213 @ $1.87 | $780.2K |
| Oct 13, 26 | Rosenthal Arnon | director, officer: Chief Executive Officer | A-Award | 275,000 @ $1.87 | $514.3K |
| Oct 13, 26 | Rosenthal Arnon | director, officer: Chief Executive Officer | A-Award | 132,500 @ $1.87 | $247.8K |
FY2021 · 10-K disclosure
Stock news · updated daily
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (“Alector,” Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the pricing of an underwritten offering of common stock. Alector is selling 36,600,000 shares of common stock. The shares of common stock are being sold at an offering price of $2.05 per share, which represents a premium of approximately 7.3% over the closing price on October 15, 2026. The gross proceeds to Alector from this offering are expected to be $75,030,000.00 before deducting the underwriting discounts and commissions and other estimated offering expenses. All shares of common stock to be sold in the offering are being offered by Alector. The offering is expected to close on or about October 19, 2026, subject to the satisfaction of customary closing conditions.
| 4 | Oct 15, 2026 | 2026-10-15 16:05:10 | View |
| 4 | Oct 15, 2026 | 2026-10-15 16:05:07 | View |
| 4 | Oct 15, 2026 | 2026-10-15 16:05:05 | View |
| 8-K | Oct 14, 2026 | 2026-10-14 09:00:14 | View |
| 8-K | Oct 5, 2026 | 2026-10-05 07:00:14 | View |
| SC 13G | Sep 18, 2026 | 2026-09-18 16:57:12 | View |
Proxy statement (DEF 14A) disclosures
Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -0.23 | -0.21 | Beat 8.1% | $3.32M |
| May 7, 2026 | -0.35 | -0.21 | Beat 40.0% | $1.05M |
| Feb 25, 2026 | -0.39 | -0.34 | Beat 12.8% | $6.24M |
| Nov 6, 2025 | -0.42 | -0.34 | Beat 19.0% | $3.26M |
| Aug 7, 2025 | -0.45 | -0.30 | Beat 33.3% | $7.87M |
| May 8, 2025 | -0.44 | -0.41 | Beat 6.8% | $3.67M |
TTM vs. 5-year historical average (annual ratios)
| Metric | ALEC | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.7x | -11.9x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -4.8x | EPS est. -0.38 | Elevated |
| Price / Book | -20.4x | 4.1x | Discount |
| Price / Sales | 14.7x | 6.0x | Elevated |
| EV / EBITDA | -1.6x | -12.5x | Discount |
| Return on equity | -531.0% | — | Weak |
| Gross margin | 100.0% | 33.7% | Above hist. |
| Debt / Equity | -3.29 | 0.43 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -7.43 | Distress |
Discounted cash flow model
